MEI Pharma (MEIP) Year-over-year earnings per share growth for the last twelve months

MEI Pharma, Inc. (MEIP) capital is exposed to geopolitical risks that hinder global testing and patent protection. The quarterly EPS dynamics on the GURU.Markets system summary chart demonstrate sideways stagnation, where 71.70 reflects the latest metric value. Stability of raw material supply is guaranteed by the diversification of channels, and the creation of a targeted therapy network makes the company a significant center in the fight against resistant tumors.

MEI Pharma (MEIP) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 09/11/2025

Analytical breakdowns for MEI Pharma, Inc.

- market value and analyst target forecast:

Price Chart MEI Pharma|MEIP - Average Forecast Price

- market capitalization details:

Market Value MEI Pharma Corp|MEIP - Total Enterprise Value

- book capitalization data:

Book Value per Share MEI Pharma|MEIP - Accounting Capitalization|Market Value to Book Value Ratio meipharma.com|MEIP - Cumulative Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

MEIP - Final Profit|Projected Future Earnings MEI Pharma, Inc.|MEIP - P/E Multiple|Future Price to Earnings MEI Pharma Corp|MEIP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MEI Pharma Corp|MEIP - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) MEI Pharma|MEIP - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months meipharma.com|MEIP - Earnings per share increase in current year|Earnings growth forecast for next year MEI Pharma, Inc.

Analysis of all company metrics:MEI Pharma, MEIP

Flagship merchandise of MEI Pharma Corporation

MEI Pharma, Inc. (MEIP) is laying the foundation for long-term monopoly margins through the development of innovative hematological drugs with strong patent protection. This metric measures the rate of change in net earnings per share between quarters, transforming accounting results into a leading indicator where positive quarterly EPS momentum confirms the issuer's financial stability and growth in valuation.

Who MEI Pharma, Inc. competes with

TG Therapeutics (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Inc (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Corp|Earnings per share growth in annualized terms for the last twelve months Syndax Corp SNDX|Quarterly EPS earnings growth KURA|adctherapeutics.com - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Foghorn Therapeutics Inc. FHTX|VOR - Year-over-year net earnings per share growth for the last 12 months|Nkarta Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Coeptis Therapeutics|ATNM: Quarterly EPS earnings growth|ESLA - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months CASI|MRKR: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months IN8bio, Inc (INAB)|ERNA: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth GTBP (GT Biopharma, Inc.)|Year-over-year earnings per one share growth for the last 12 months APTO|Bio-Path Holdings, Inc. - Quarterly EPS earnings growth|VINC - Quarterly EPS earnings growth